Home / Executive Moves / Former ASRC Federal Chief, CACI EVP Paul Dillahay Named NCI CEO

Former ASRC Federal Chief, CACI EVP Paul Dillahay Named NCI CEO

Paul Dillahay
Paul Dillahay

Paul Dillahay, a 15-year GovCon management veteran and a former executive vice president at CACI International (NYSE: CACI), has joined Reston, Virginia-based government technology services contractor NCI (Nasdaq: NCIT) as president and CEO in a move that takes effect immediately.

NCI said Monday Dillahay succeeds former president and chief executive Brian Clark, who took the CEO role in October 2015, and will also join the company’s board of directors.

NCI reported $333.09 million in 2015 revenue and expects to report $320 million-$326 million in total sales for this year as of the company’s third quarter financial statement issued Oct. 26.

Dillahay previously served as EVP for CACI’s health and litigation solutions group and prior to that helped lead corporate development functions at the Arlington, Virginia-based company in support of its merger-and-acquisition strategy.

Prior to CACI, he led Greenbelt, Maryland-based government services contractor ASRC Federal as CEO and held the chief operating officer post there before his appointment to the chief executive post.

Dillahay’s GovCon career also includes roles such as COO of the former US Investigation Services and head of an operation support business at Lockheed Martin (NYSE: LMT).

Shares in NCI were down 1.88 percent to $11.72 as of 11 a.m. Eastern time at respective declines of 11.54 percent year-to-date and 16.97 percent over 12 months.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.